We are live on ! Find out more
PACB icon

Pacific Biosciences

128 hedge funds and large institutions have $580M invested in Pacific Biosciences in 2016 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 42 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

34% more capital invested

Capital invested by funds: $432M → $580M (+$148M)

14% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 42

9% less funds holding

Funds holding: 141128 (-13)

21% less call options, than puts

Call options by funds: $5.52M | Put options by funds: $7M

39% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 31

Holders
128
Holders Change
-13
Holders Change %
-9.22%
% of All Funds
3.42%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
19
Increased
48
Reduced
42
Closed
31
Calls
$5.52M
Puts
$7M
Net Calls
-$1.48M
Net Calls Change
+$105K
Name Holding Trade Value Shares
Change
Change in
Stake
FRM
151
Fox Run Management
Connecticut
-$106K -15,000 Closed
Verition Fund Management
152
Verition Fund Management
Connecticut
-$106K -15,000 Closed
SCM
153
Stevens Capital Management
Pennsylvania
-$104K -14,801 Closed
BFM
154
Boothbay Fund Management
New York
-$92K -13,080 Closed
Teacher Retirement System of Texas
155
Teacher Retirement System of Texas
Texas
-$73K -10,434 Closed
Federated Hermes
156
Federated Hermes
Pennsylvania
-$4K -576 Closed
PNC Financial Services Group
157
PNC Financial Services Group
Pennsylvania
-$3K -380 Closed
MA
158
MUFG Americas
New York
-$2K -329 Closed
MAM
159
Meeder Asset Management
Ohio
-$1K -176 Closed

PACB Hedge Fund Activity: Q3 2016 in Review

128 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2016, worth a combined $580M — up 34% from $432M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of PACB and 19 opened new positions — a net loss of 12 holders — while 42 trimmed existing stakes and 48 added.

The largest buyer was Oracle Investment Management, adding an estimated $15.2M. The largest seller was Millennium Management, cutting an estimated $23.6M.

  • 128 institutional investors held Pacific Biosciences (PACB) as of Q3 2016, down from 141 in Q2 2016.
  • Funds reported $580M of Pacific Biosciences stock for Q3 2016, up 34% quarter-over-quarter.
  • 19 funds opened new Pacific Biosciences positions in Q3 2016 and 31 closed out, a net change of -12 holders.
  • The largest Pacific Biosciences buyer in Q3 2016 was Oracle Investment Management, an estimated $15.2M added.
  • The largest Pacific Biosciences seller in Q3 2016 was Millennium Management, an estimated $23.6M sold.

Based on aggregated 13F filings for Q3 2016.